Second Sight reported $8.9 million in total revenue in 2015, a 163% increase from $3.4 million reported in 2014, according to a press release. The increase was attributed to a higher number of Argus II retinal prostheses implanted in 2015.
Author: Healio ophthalmology
31st APAO Congress
The 31st APAO Council Meeting, held on March 23, resulted in meaningful discussions and decisions about the society’s future activities and plans.This new initiative, called Strengthening Eye Health Care Services in Lao PDR 2016, will involve the cooperation of many agencies from Laos and around the Asia-Pacific, with APAO serving as a facilitator. Other participating groups include the Asia Pacific Council of Optometry, Christian Blind Mission, Brien Holden Vision Institute, Eye Care Foundation, Fred Hollows Foundation, Optometry Giving Sight, Royal Australian and New Zealand College of Ophthalmologists and SightLife. In (Read more...)
Genetic factors, vitamin C intake influence cataract progression
Researchers reported the progression of nuclear cataract over a 10-year period is influenced by genetic factors, with a heritability of 35% in addition to vitamin C and manganese intake, according to a study in Ophthalmology. The cross-sectional nuclea…
Iridex receives two patents for laser delivery system
The U.S. Patent Office has issued two patents for the TxCell scanning laser delivery system to cover key elements of Iridex’s MicroPulse technology and to improve the delivery of its subthreshold treatment for patients with glaucoma and retinal diseases, Iridex announced in a press release. The two patents, No. 9,265,656 and No. 9,278,029, will cover automatic laser delivery with multi-spot pattern scanning for retinal photocoagulation that spares tissue and enables faster treatments.
Long-term results of glaucoma micro-stent encouraging
Implantation of the CyPass micro-stent provides long-term control of IOP and a significant reduction in medication, according to one surgeon.“The effect is durable. I have the most patients with 7 years of follow-up, and reduction of IOP is on average the same that was achieved a few days after the operation. The reduction of medications is as well consistent, from three to four before to one or two after, or even no medications at all,” Magda Rau, MD, OSN Europe Edition Associate Editor, told Ocular Surgery News.
VIDEO: Addressing corneal issues at the time of cataract surgery
At OSN New York, Thomas John, MD, talks about corneal issues that can affect cataract surgery outcomes.
VIDEO: Surgeon shares pearls on IOL calculations, astigmatism correction
At OSN New York, Douglas D. Koch, MD, shares pearls on IOL calculations and astigmatism correction.
VIDEO: Speakers discuss real-time operations, metrics in the ophthalmic practice
At OSN New York, Brett Chambers and Mark Johnson discuss how to use technology to generate useful metrics to empower staff and add to bottom line.
ACP makes Medicaid expansion waiver recommendations to ‘best suit patients’
The ACP has released a position paper that reviews and makes recommendations on Medicaid expansion waivers to offer patients better coverage.The paper, Medicaid Expansion: Premium Assistance and Other Options, offered recommendations about information …
ACP makes Medicaid expansion waiver recommendations to ‘best suit patients’
The ACP has released a position paper that reviews and makes recommendations on Medicaid expansion waivers to offer patients better coverage.The paper, Medicaid Expansion: Premium Assistance and Other Options, offered recommendations about information …
Study: Individualized ranibizumab regimen improves visual acuity in patients with CRVO
Individualized dosing of ranibizumab guided by stabilization criteria significantly improved best corrected visual acuity in patients with macular edema secondary to central retinal vein occlusion, a study found.The prospective, single-arm CRYSTAL stud…
QLT reports $23.3 million operating loss in 2015
QLT reported an operating loss of $23.3 million, or $0.44 per share, in 2015 compared with $3.8 million, or $0.08 per share, in 2014, according to a press release. In 2014, Auxilium paid a termination fee of $28.4 million, more than the $2.7 million In…
CDC issues interim guidelines for treatment of Ebola survivors
The CDC released interim guidelines for the treatment of Ebola survivors who have fully recovered and seek subsequent care.Special consideration is merited for procedures that create the opportunity for contact with certain bodily fluids and tissues in…
VIDEO: Femtosecond laser cataract surgery in glaucoma patients
At OSN New York, Robert Noecker, MD, gives pearls on performing femtosecond laser cataract surgery on glaucoma patients.
VIDEO: Maintaining pupil size during cataract surgery
At OSN New York, Cynthia A. Matossian, MD, discusses the benefits of using Omero’s Omidria phenylephrine and ketorolac injection for maintaining the patient’s pupil size during cataract surgery.
VIDEO: Efficient use of technology recources
At OSN New York, Jane T. Shuman discusses the use of technology to improve efficiencies in the ophthalmic practice.
VIDEO: Pearls from a tough cataract case
At OSN New York, Douglas D. Koch, MD, reviews a case of a 48-year old male patient who had a self-inflicted knife wound as a child who was seeking cataract surgery to improve vision and cosmesis.
In France, use of intracameral antibiotics increases while cases of acute postoperative endophthalmitis decrease
Increased use of intracameral antibiotic injections yielded a decreased incidence of acute postoperative endophthalmitis after phacoemulsification over a 10-year period, according to a study in France.Investigators used data from a national administrat…
NovaBay reports $19 million net loss in 2015
NovaBay reported a net loss of $19 million, or $6.82 per share, in 2015 compared with a net loss of $15.2 million, or $7.65 per share, in 2014, according to a press release. The larger net loss was attributed to increased spending on sales and marketin…
RetroSense Therapeutics doses first patient in phase 1/2 clinical study of RST-001
The first patient has been dosed in a phase 1/2 clinical study of RST-001, a gene therapy designed to restore vision in patients with retinitis pigmentosa, according to a press release from RetroSense Therapeutics.In the first part of the study, three …